Stay updated with breaking news from Point Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Equities researchers at Chardan Capital started coverage on shares of Oyster Point Pharma (NASDAQ:OYST – Get Rating) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $22.00 price target on the stock. Chardan Capital’s price target would indicate a potential upside of 213.84% from […]
11.08.2022 - TYRVAYA (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $4.7 Million in Q2’22Approximately 30,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 5,700 Unique Eye Care Professionals; Launch to ...
Scientific Poster Examines Effects of Treatment in Broad Spectrum of Dry Eye Disease Patients...
Oyster Point Pharma (NASDAQ:OYST – Get Rating) had its price target cut by analysts at Piper Sandler from $60.00 to $15.00 in a research report issued on Friday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 271.29% from the stock’s current price. Separately, Zacks Investment Research upgraded shares of Oyster […]
Oyster Point Pharma (NASDAQ:OYST – Get Rating) and Qiagen (NASDAQ:QGEN – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. Institutional & Insider Ownership 86.3% of Oyster Point Pharma shares […]